Pomalyst



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 60.7%
Plasma Cell Myeloma 33.9%
Pain 1.2%
Nausea 0.7%
Hypertension 0.6%
Prophylaxis 0.5%
Anxiety 0.4%
Constipation 0.2%
Insomnia 0.2%
Amyloidosis 0.2%
Antiviral Prophylaxis 0.2%
Chronic Obstructive Pulmonary Disease 0.2%
Deep Vein Thrombosis 0.2%
Haemorrhoids 0.2%
Infection Prophylaxis 0.2%
Neutropenia 0.2%
Vomiting 0.2%
Analgesic Therapy 0.1%
Atrial Fibrillation 0.1%
Dyspnoea 0.1%
Death 24.1%
Plasma Cell Myeloma 23.0%
Pneumonia 8.9%
White Blood Cell Count Decreased 5.8%
Rash 5.5%
Pruritus 3.4%
Full Blood Count Decreased 3.1%
Pancytopenia 3.1%
Pyrexia 2.4%
Renal Failure 2.4%
Unevaluable Event 2.4%
Platelet Count Decreased 2.2%
Thrombocytopenia 2.2%
Drug Intolerance 1.9%
Thrombosis 1.9%
Neuropathy Peripheral 1.7%
Renal Disorder 1.7%
Sepsis 1.7%
Fatigue 1.4%
Oedema Peripheral 1.4%
Secondary
Product Used For Unknown Indication 69.0%
Plasma Cell Myeloma 20.3%
Pain 2.0%
Nausea 1.2%
Prophylaxis 1.1%
Anxiety 0.7%
Hypertension 0.6%
White Blood Cell Count Decreased 0.6%
Deep Vein Thrombosis 0.5%
Blood Pressure 0.4%
Diarrhoea 0.4%
Haematocrit Decreased 0.4%
Haemoglobin Decreased 0.4%
Haemorrhoids 0.4%
Neutrophil Count Decreased 0.4%
Platelet Count Decreased 0.4%
Constipation 0.3%
Insomnia 0.3%
Neuropathy Peripheral 0.3%
Supplementation Therapy 0.3%
Plasma Cell Myeloma 25.0%
Pancytopenia 17.2%
Death 14.8%
White Blood Cell Count Decreased 5.5%
Sepsis 4.7%
Pneumonia 3.9%
Bone Marrow Failure 3.1%
Femur Fracture 3.1%
Drug Ineffective 2.3%
Hyperventilation 2.3%
Pyrexia 2.3%
Septic Shock 2.3%
Thrombosis 2.3%
Clostridium Difficile Colitis 1.6%
Full Blood Count Decreased 1.6%
Gait Disturbance 1.6%
Invasive Ductal Breast Carcinoma 1.6%
Myalgia 1.6%
Myocardial Infarction 1.6%
Neuropathy Peripheral 1.6%
Concomitant
Product Used For Unknown Indication 79.4%
Amyloidosis 8.8%
Plasma Cell Myeloma 8.8%
Hiv Infection 2.9%
Plasma Cell Myeloma 50.0%
Thrombophlebitis Superficial 25.0%
Thrombosis 25.0%
Interacting
Plasma Cell Myeloma 50.0%
Product Used For Unknown Indication 50.0%
Death 100.0%